What This Article Covers
This article summarizes published research on CJC-1295 with DAC for technical review. It separates direct human biomarker evidence, review and detection literature, and limitations so the reader can see what was actually tested before seeing the boundaries.
Bottom Line
CJC-1295 with DAC has direct human biomarker evidence in healthy adults. In randomized, placebo-controlled, double-blind ascending-dose studies, a long-acting CJC-1295 GHRH analog produced sustained increases in growth hormone and IGF-I biomarkers. That is pharmacodynamic evidence, not proof of broad clinical outcomes.
What Was Tested in Humans?
A 2006 study evaluated CJC-1295 as a long-acting analog of growth-hormone-releasing hormone in healthy adults. The publication describes two randomized, placebo-controlled, double-blind, ascending-dose trials lasting 28 and 49 days. After a single injection, mean plasma growth hormone increased dose-dependently for six days or more, and mean IGF-I increased for nine to eleven days. The estimated half-life was 5.8 to 8.1 days. After repeated dosing, mean IGF-I remained above baseline for up to 28 days. The abstract reports no serious adverse reactions in the studied setting [pubmed:16352683].
A 2009 biomarker study analyzed serum from 11 healthy young adult men before and one week after CJC-1295 injection. The study used two-dimensional gel electrophoresis and mass spectrometry to evaluate serum protein-profile changes associated with GH/IGF-1 axis activation [pubmed:19386527].
These human sources establish pharmacokinetic and pharmacodynamic biomarker findings in defined study populations. They do not establish broad clinical efficacy or safety for unstudied contexts.
What Do Reviews and Evidence Syntheses Add?
Recent reviews discuss CJC-1295 with DAC as part of the broader growth hormone/IGF-1 axis and peptide-market landscape [pubmed:42395176]. This context is useful for understanding why the compound is discussed, but review-level statements do not substitute for controlled outcome trials.
What Did Analytical and Mechanistic Studies Show?
A 2021 detection-methods study evaluated in vitro metabolism and liquid chromatography-tandem mass spectrometry detection of growth-hormone-releasing hormone analogs, including CJC-1295 and CJC-1295 with drug affinity complex, in fortified urine. This is analytical and anti-doping methodology, not efficacy evidence [pubmed:34665524].
Mechanistically, the human biomarker findings align with GH/IGF-1 axis activation, but biomarker movement is not the same thing as demonstrated clinical benefit.
How the Evidence Fits Together
The practical reading for CJC-1295 with DAC is evidence hierarchy. The best direct human evidence is biomarker-focused, not outcome-focused. Reviews and analytical studies add context, but they do not broaden the conclusions beyond the studied design, population, and endpoints.
What Is Not Established
- Broad human efficacy for CJC-1295 with DAC is not established by the selected source set.
- GH and IGF-I increases do not, by themselves, prove clinical benefit.
- Long-term safety, dosing generalizability, and outcomes in unstudied populations are not established here.
- Dosing, treatment, diagnostic, veterinary, or administration guidance is outside the scope of KRL materials.
Research-Use Boundary
This article summarizes published research and regulatory-source discussion for technical review. It is not medical advice, not a dosing guide, and not a recommendation for human or veterinary use. KRL materials are sold for research use only and are not for diagnostic, therapeutic, or administration purposes.
Selected Sources
- [pubmed:16352683] Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. https://pubmed.ncbi.nlm.nih.gov/16352683/
- [pubmed:19386527] Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. https://pubmed.ncbi.nlm.nih.gov/19386527/
- [pubmed:34665524] Advances in the detection of growth hormone releasing hormone synthetic analogs. https://pubmed.ncbi.nlm.nih.gov/34665524/
- [pubmed:42395176] The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis. https://pubmed.ncbi.nlm.nih.gov/42395176/
Related KRL Resources
Need current product documentation or small-order review? Small-quantity qualified research purchasers can send a KRL10 order-review request, request current COA availability, review product documentation, or use the catalog-access support path from Kratos Research Labs.
1st Time Customers Receive 10% off their 1st order over $100.00 with CODE KRL10
Research use only. Not for human or veterinary use. Payment instructions are provided after compliance review.